
|Videos|May 15, 2017
Results of Buparlisib Plus Fulvestrant in HR+/HER2- Breast Cancer
Ruth O’Regan, MD, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
4
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
5








































